Potential clinical utility of plasma D-dimer levels among women with cervical cancer in Lagos, Nigeria
- PMID: 36816787
- PMCID: PMC9937069
- DOI: 10.3332/ecancer.2023.1501
Potential clinical utility of plasma D-dimer levels among women with cervical cancer in Lagos, Nigeria
Abstract
The link between plasma D-dimer levels and underlying malignancy has been established. How this translates in clinical practice as a marker of detection and prognosis of cervical cancer (CC) is still unknown. This study compared the plasma D-dimer levels in women with and without CC and assessed the associations between plasma D-dimer levels and the stage and grade of CC. It was a comparative cross-sectional study of 65 women with histological diagnosis of CC and an equal number of age-matched cancer-free women enrolled at the University Teaching Hospital in Lagos, Nigeria. Participants' sociodemographic and clinical data as well as venous blood samples for estimation of plasma D-dimer were collected for statistical analyses. A receiver operating characteristic (ROC) analysis is performed to select the cut-off value of plasma D-dimer for differentiating CC from non-cancer. There was a statistically significant difference in the median levels of plasma D-dimer of women with CC and their cancer-free comparison groups (3,120 (1,189-4,515) versus 210 (125-350) ng/mL; p = 0.001). A plasma D-dimer value of 543 ng/mL was chosen in a ROC analysis as the discriminatory cut-off to differentiate CC from non-cancer. There were significant associations between plasma D-dimer levels and the International Federation of Gynaecology and Obstetrics stage (p = 0.001) or grade (p = 0.001) of CC. The study, therefore, demonstrated the potential clinical usefulness of plasma D-dimer as a diagnostic and prognostic marker of CC.
Keywords: FIGO stage; Lagos; ROC; cervical malignancy; marker.
© the authors; licensee ecancermedicalscience.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- Okunade KS, Adejimi AA, John-Olabode SO, et al. An overview of HPV screening tests to improve access to cervical cancer screening amongst underserved populations: from development to implementation. Risk Manag Healthc Policy. 2022;15:1823–1830. doi: 10.2147/RMHP.S296914. [Internet] - DOI - PMC - PubMed
-
- Güzel C, van Sten-Van’t Hoff J, de Kok IMCM, et al. Molecular markers for cervical cancer screening. Exp Rev Proteomics. 2021. [24/09/22]. [ https://www.tandfonline.com/action/journalInformation?journalCode=ieru20] - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources